Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

Autor: Igor V. Samoylenko, Yulia M. Kolontareva, Ekaterina V. Kogay, Natalia V. Zhukova, Igor A. Utyashev, Mikhail E. Ivannikov, Konstantin V. Menshikov, Maxim V. Zinkevich, Kristina V. Orlova, Yulia V. Vakhabova, Mikhail V. Volkonsky, Natalia A. Beliaeva, Ivan I. Butkov, Elena V. Karabina, Tatyana L. Moskovkina, Kseniya A. Moshkova, Olga V. Plishkina, Vitaliy D. Sychev, Oxana S. Cheplukhova, Vera V. Chernova, Alexandr N. Yurchenkov, Ksenia G. Babina, Nikita A. Savelov, Lev V. Demidov

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

BackgroundAmong several treatment options for BRAF-mutant metastatic melanoma, a combination of BRAF inhibitor, MEK inhibitor, and anti-PDL1 antibody seems to be a new emergent approach recently registered in the Russian Federation. It is still not c

Externí odkaz: https://doaj.org/article/91fe8f49496a4d33a30456c3a9114984

Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia

Autor: Kristina V. Orlova, Mikhail Iu. Fedyanin, Konstantin E. Simanenkov, Aleksandr S. Dergunov, Petr R. Goldshmidt, Aleksandra F. Saydullaeva, Darya V. Bogacheva, Marina A. Yavorskaya, Artur Z. Azanov, Alexander A. Fedenko, Larisa V. Bolotina, Tatyana I. Deshkina, Kseniya G. Babina, Ekaterina A. Kuzevanova, Liudmila G. Zhukova, Polina S. Feoktistova, Natalya I. Polshina, Ekaterina V. Peganova, Valentina E. Shikina, Maksim M. Sobolev, Oleg V. Mironov, Vera A. Vaschenko, Mariya M. Ershova, Agniya O. Mezhueva, Svetlana A. Orlova, Denis A. Tantsyrev, Darya K. Taskina, Antonina A. Teterich, Elena V. Karabina, Yuliya V. Kostalanova, Marina V. Bogacheva, Natalia V. Zhukova, Rashida V. Orlova, Maksim V. Zinkevich, Aleksandr I. Kazmin, Mikhail V. Volkonskiy, Liya M. Voronkova, Anastasiya S. Karpova, Mikhail L. Maleyko, Mariya N. Gorshenina, Elena I. Kryuchkova, Fedor V. Moiseenko, Yuliya I. Murzina, Shamil I. Musin, Andrey N. Ogloblin, Mariya S. Perminova, Regina A. Dumbrava, Sergey A. Emelyanov, Svetlana A. Protsenko, Alexander V. Sultanbaev, Anna V. Tarasova, Elena B. Shakhnovich, Marina V. Demchenkova, Yuliya A. Lozovskaya, Khedi S. Musaeva, Elena M. Pavlova, Roman A. Skotnikov, Vera V. Chernova, Angelina S. Chichkanova, Adina M. Akhmatova, Marina A. Zafirova, Andrey A. Mischenko, Elena N. Ovsienko, Viktoriya A. Petrukhnenko, Oksana A. Syusyukaylova, Yana A. Tyugina, Elena A. Shumilkina, Daniil L. Stroyakovskiy, Aleksandr N. Yurchenkov, Pavel L. Baldin, Anastasiya S. Belova, Olga V. Diduk, Elena A. Konovalova, Lyudmila N. Lebedeva, Yaroslav A. Li, Viktoriya V. Mashtapa, Yana A. Mironenkova, Kristina V. Narovenkova, Olga A. Pavlikova, Elvira L. Parsadanova, Irina S. Pimonova, Anna A. Ruzhnikova, Irina D. Sivunova, Ekaterina P. Soloveva, Maksim I. Sosnin, Kh. Toita Temirsultanova, Makhabbat Zh. Tyulegenova, Aleksandra V. Khodkevich, Nadezhda R. Shakurova, Sureya N. Efendieva, Karine L. Avagimyan, Ekaterina Р. Anokhina, Mariya I. Antoshkina, Stanislav M. Borzyanitsa, Samir K. Dzhentemirov, Marina V. Dmitrochenko, Alla V. Zheleznyak, Yuliya V. Komoza, Aleksandr S. Kopanev, Tatyana I. Kornienko, Margarita A. Krasilnikova, Darya A. Lukhmanova, Natalya S. Mazur, Polina M. Markina, Zhargal S. Mitapov, Svetlana N. Osodoeva, Irina A. Prokopenko, Irina M. Radyukova, Madina S. Ramazanova, Alfiya R. Safarova, Mariya A. Safronova, Khalimat M. Khabrieva, Natalya S. Tsygankova, Kseniya V. Chermakova, Tatyana A. Chirkova, Igor V. Samoylenko, Valeria V. Nazarova, Angelina E. Akhmetyanova, Lev V. Demidov

Publikováno v: Современная онкология, Vol 26, Iss 1, Pp 20-34 (2024)

Background. Prior to the introduction of new agents — immune checkpoint inhibitors — for inoperable and/or metastatic melanoma (IMM), chemotherapy outcomes were generally poor. The median (Me) overall survival (OS) in IMM was no more than 6-9 mon

Externí odkaz: https://doaj.org/article/fff40d04a39d498ba7ec6262154c7020

Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

Autor: Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova

Publikováno v: Современная онкология, Vol 23, Iss 1, Pp 68-76 (2021)

Relevance. Data on the efficacy of endocrine and chemotherapy regimens in patients with hormone-resistant metastatic breast cancer (mBC) after progression with CDK4/6 inhibitors are limited; the search for an effective therapy regimen in this clinica

Externí odkaz: https://doaj.org/article/714a7172db8b443795259379d343327b

The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience

Autor: Irina V Kolyadina, Irina S Bulavina, Vladislav V Petkau, Natalia V Strakhova, Vera A Gorbunova, Elena I Kovalenko, Liudmila V Manziuk, Elena V Artamonova, Liudmila G Zhukova, Larisa V Bolotina, Inna P Gan'shina, Tatiana Iu Semiglazova, Aleksei G Manikhas, Natalia A Raevskaia, Ilia M Itkin, Svetlana V Khokhlova, Dmitrii V Filonenko, Viktor E Gol'dberg, Natalia O Popova, Dmitrii M Ponomarenko, Valentina E Shikina, Liubov I Vladimirova, Natalia M Tikhanovskaia, Elena V Karabina, Guzel Z Mukhametshina, Alfiia I Khasanova, Sufiia Z Safina, Mikhail V Shaidorov, Andrei E Orlov, Iuliia V Kostalanova, Natalia V Levchenko, Mikhail A Osipov, Tatiana V Karandeeva, Irina V Evstigneeva, Igor S Chernov, Dzheims Dzh Kolokolov, Anton Iu Povyshev, Alina S Shatokhina, Elena M Cherniakova, Oksana N Shkodenko, Evgeniia S Kuz'mina

Publikováno v: Современная онкология, Vol 21, Iss 2, Pp 17-24 (2019)

Aim. Eribulin is an active cytostatic, associated with a wide range of mechanisms of antitumor effects, but eribulin efficiency and safety in patients with breast cancer (BC), associated with cerebral metastases are still poorly understood. Materials

Externí odkaz: https://doaj.org/article/5f21fe71ca7c49f6a857b2579dfadccd